Receptor radionuclide therapy with 177Lu-DOTATOC (177Luedotreotide or 177Lu-octreotide) in SSTR positive patients: A multicentre, prospective, phase II trial

#4533

Introduction: For advanced G1-G2 GEP-NET patients, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE can be recommended. However, there are several SSTR-positive tumours for which PRRT has previously shown efficacy that are not currently covered by the indications for 177Lu-DOTATATE in Italy and, therefore, cannot benefit from it. Less used and studied is the 177Lu-DOTATOC. This is a radiopeptide with excellent safety and efficacy profile in PRRT and certainly not lower than 177Lu-DOTATATE.

Aim(s): The main objective is to evaluate the efficacy, safety, PFS, OS and quality of life of 177Lu-DOTATOC treatment in SSTR positive tumours.

Materials and methods: Patients must have histologically or cytologically confirmed sst2-positive tumours. Diagnostic PET/CT 68Ga peptide images must show significant uptake in the tumours. Patients must have progressive and measurable disease according to RECIST 1.1 criteria. Patients must have adequate haematological, hepatic and renal function. Thanks to the GMP facility IRST Radiopharmaceutical Therapy Factory (RTF), we are able to produce experimental 177Lu-DOTATOC.

Conference:

Presenting Author: Sansovini M

Authors: Sansovini M, Nicolini S, Grassi I, Marini I, Matteucci F,

Keywords: Lu-dotatoc, Radiopharaceutical Therapy Factory, SSTR positive tumour,